News Headlines

  1. Zynerba Pharmaceuticals Announces Positive Meeting With U.S. Food And Drug Administration And Plans To Conduct A Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support An NDA Filing

    Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the results of a positive meeting held with the U.S. Food and Drug Administration (FDA) regarding its planned development strategy for ZYN002 in Fragile X syndrome (FXS).

  2. G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

    G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data from its Phase 2a trial evaluating trilaciclib in patients undergoing chemotherapy for first-line small cell lung cancer (SCLC).

  3. Uber Launches Uber Health, A B2B Ride-Hailing Platform For Healthcare

    Uber’s launching a new business line called Uber Health on Thursday that will provide a ride-hailing platform available specifically to healthcare providers, letting clinics, hospitals, rehab centers and more easily assign rides for their patients and clients from a centralized dashboard – without requiring that the rider even have the Uber app, or a smartphone.

  4. Elligo Health Research And Saama Technologies Announce Strategic Partnership To Advance Clinical Research Data Management

    Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, is partnering with Saama Technologies, Inc., a leading clinical data analytics company, to improve awareness of, access to, and participation in clinical trials for U.S. physicians and patients.

  5. Immuno-Oncology Clinical Trials Increased At 17% Average Yearly Growth Between 2008 And 2017, Says GlobalData

    Analysis of global clinical trials in immuno-oncology (IO) for 2008–2017 reveals that they increased at a Compound Annual Growth Rate (CAGR) of 17% over the 10-year period, according to GlobalData, a leading data and analytics company.

  6. Galera Therapeutics Announces Dosing Of First Patient In Phase 1/2 Pancreatic Cancer Clinical Trial Of GC4419

    Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced the first patient with locally advanced pancreatic cancer (LAPC) has been dosed in a Phase 1/2 clinical trial of lead candidate GC4419, a highly selective and potent small molecule dismutase mimetic, at The University of Texas MD Anderson Cancer Center in Houston, Texas.

  7. CicloMed Announces First Patient Dosed With Ciclopirox Prodrug In Phase I Trial In Patients With Advanced Solid Tumors

    CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced that the first patient has been dosed in a Phase I clinical trial.

  8. Excellent Cohort A Data From Final Primary Evaluation Period In Cynata GvHD Phase 1 Clinical Trial

    Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD).

  9. Melinta Therapeutics Publishes Complete Results From Phase 3 TANGO I Study Of VABOMERE™ (Meropenem And Vaborbactam) In Patients With cUTI

    Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that results from the Phase 3 TANGO I study of VABOMERE™ (meropenem and vaborbactam) for injection were published in the Journal of the American Medical Association (JAMA).

  10. Reata Provides Program Update On Phase 2 Rare Renal Clinical Trials

    Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today provided guidance on the timing of data announcements from the ongoing Phase 2 PHOENIX and CARDINAL trials of bardoxolone methyl (“bardoxolone”) in rare forms of chronic kidney disease (“CKD”).